Roquefort Therapeutics PLC (LSE:ROQ) chairman Stephen West talks to Proactive London about LYRAMID, their research and development subsidiary which has identified lead compounds that it will take forward for lab-based experiments to test their efficacy in altering cancer cell properties.
Midkine is a growth factor that is thought to play a key role in disease development, further work is currently being carried out to gather more data on the ability of these candidate drugs to modify midkine expression.
LYRAMID is exploring the use of midkine inhibitors to reverse the resistance to cancer immunotherapy drugs such as checkpoint inhibitors.